Japan’s New Agency Selects Certara Solution

Published on: 

Applied Clinical Trials

Certara announced that Japan’s new Agency for Medical Research and Development (AMED) has selected its Phoenix® WinNonlin® software for pharmacokinetic/pharmacodynamic (PK/PD) modeling and non-compartmental analysis of new drug candidates. AMED was launched on April 1, 2015 and fulfills a similar role to the National Institutes of Health in the United States. AMED is expected to employ Phoenix WinNonlin to create PK profiles, and assess bioavailability for new drug candidates in its preclinical program to discover which hold the most therapeutic potential and should be progressed into clinical trials.

Read the full release.